Nuformix PLC Result of AGM (2682X)

TIDMNFX

RNS Number : 2682X

Nuformix PLC

25 August 2022

Nuformix plc

Result of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual General Meeting of Nuformix plc was held earlier today and all resolutions put to shareholders were duly passed and approved on a show of hands at the meeting. The results of the proxy voting position received in advance of the meeting are reported below:

 
                  Resolution               Ordinary/       For                Against              Total 
                                            Special                                              votes cast 
                                                         No. of        %      No. of      % 
                                                          votes                votes 
      To receive the annual 
       report and accounts 
       for the year ended 
 1     31 March 2022                       Ordinary    150,018,268    100        0        0     150,018,268 
      To approve the Remuneration 
 2     Policy                              Ordinary    149,469,749   99.86    217,007    0.14   149,686,756 
      To re-appoint Julian 
 3     Gilbert as a director               Ordinary    150,096,308   99.93    106,121    0.07   150,202,429 
      To re-appoint s 
       Madeleine Kennedy 
 4     as a director                       Ordinary    150,096,308   99.93    106,121    0.07   150,202,429 
      To re-appoint Jeffreys 
       Henry Audit Limited 
 5     as auditor                          Ordinary    150,096,308   99.93    106,121    0.07   150,202,429 
                 To authorise the 
                  Directors to determine 
 6                the auditor's fees.      Ordinary    149,295,087   99.40    907,342    0.60   150,202,429 
      To authorise the 
       Directors to allot 
 7     shares.                             Ordinary    146,859,280   97.78   3,331,149   2.22   150,190,429 
                 To authorise the 
                  Directors to disapply 
 8                pre-emption rights.       Special    146,905,107   97.81   3,285,322   2.19   150,190,429 
                 To authorise the 
                  Company to purchase 
 9                its own shares.           Special    150,139,861   99.93    112,568    0.07   150,252,429 
          To authorise calling 
           of a general meeting 
           on 14 clear days' 
 10        notice.                          Special    150,102,429   99.93    100,000    0.07   150,202,429 
 

A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

The Company's issued share capital is 709,309,368 ordinary shares of GBP0.001 each.

Enquiries:

 
 Nuformix plc 
 Dr Daniel Gooding, Executive Director      Via IFC Advisory 
  Dr Julian Gilbert, Non-executive 
  Chairman 
 Stanford Capital Partners Limited 
 Tom Price / Patrick Claridge (Corporate 
  Finance)                                  [phone] 
 John Howes (Corporate Broking)             [phone] 
 IFC Advisory Limited 
 Tim Metcalfe                               [phone] 
  Zach Cohen                                 [e-mail] 
 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGXELFLLVLXBBV

(END) Dow Jones Newswires

August 25, 2022 09:39 ET (13:39 GMT)